Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study

被引：4

作者：

Joshua, A. M. ^{[1
]}

Gurney, H. ^{[2
]}

Retz, M. ^{[3
]}

Tafreshi, A. ^{[4
]}

Fong, P. C. C. ^{[5
]}

Shore, N. D. ^{[6
]}

Romano, E. ^{[7
]}

Augustin, M. ^{[8
]}

Piulats, J. M. ^{[9
]}

Berry, W. R. ^{[10
]}

Kolinsky, M. P. ^{[11
]}

Sridhar, S. S. ^{[12
]}

Conter, H. J. ^{[13
]}

Todenhoefer, T. ^{[14
]}

Appleman, L. J. ^{[15
]}

Wu, H. ^{[16
]}

Schloss, C. ^{[16
]}

Poehlein, C. H. ^{[16
]}

de Bono, J. S. ^{[17
]}

Yu, E. Y. ^{[18
]}

机构：

[1] St Vincents Hosp, Kinghorn Canc Ctr, Med Oncol, Sydney, NSW, Australia

[2] Macquarie Univ Hosp, Med Clin, Sydney, NSW, Australia

[3] Tech Univ Munich, Univ Rechts Isar Hosp, Urol, Munich, Germany

[4] Univ Wollongong, Oncol, Wollongong, NSW, Australia

[5] Auckland City Hosp, Med Oncol, Auckland, New Zealand

[6] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA

[7] Inst Curie, Ctr Canc Immunotherapy, Med Oncol, Paris, France

[8] Paracelsus Med Univ, Internal Med, Nurnberg, Germany

[9] Catalan Canc Inst, Med Oncol, Barcelona, Spain

[10] Duke Canc Ctr Cary, Med Oncol, Cary, NC USA

[11] Cross Canc Inst, Med Oncol, Edmonton, AB, Canada

[12] UHN Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada

[13] Univ Western Ontario, Med Oncol Hematol, Brampton, ON, Canada

[14] Studienpraxis Urol, Oncol, Nurtingen, Germany

[15] UPMC, Hematol & Oncol, Pittsburgh, PA USA

[16] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[17] Royal Marsden NHS Fdn Trust, Med Oncol, London, England

[18] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.10.437

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

217O

引用

页码：S1325 / S1325

页数：1